Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

BREEZE-AD5 phase II study of baricitinib in AD meets primary endpoint

Jan. 31, 2020

MicroCures advances burn wound healing collaborative research project

Jan. 30, 2020

TRuE-AD2 pivotal phase III study of ruxolitinib cream meets primary endpoint

Jan. 29, 2020

Daiichi Sankyo begins phase I study in Japan with DS-2741a for atopic dermatitis

Jan. 27, 2020

Phase III BREEZE-AD4 trial of baricitinib in atopic dermatitis meets primary endpoint

Jan. 27, 2020

Phase III study of AKP-01 spray in mild to moderate plaque psoriasis meets primary endpoint

Jan. 27, 2020

Japanese approval for Corectim ointment for atopic dermatitis

Jan. 24, 2020

Leo Pharma discovers JAK1 inhibitors

Jan. 23, 2020

Abeona initiates phase III study of EB-101 in recessive dystrophic epidermolysis bullosa

Jan. 14, 2020

Positive topline data from phase Ib study of CBP-201 in moderate to severe atopic dermatitis

Jan. 9, 2020

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...